论文部分内容阅读
目的:观察非清髓造血干细胞移植对慢粒慢性期(CML蛳CP)、慢粒加速期(CML蛳AP)的疗效。方法:用福达华(F)30 mg/m2×6 d,白消安(B)4 mg·kg-1·d-1×2 d,环磷酰胺(CTX)600 mg/d×2 d,±Ara蛳C对7例HLA全相合者进行预处理,并对其造血恢复等指标动态观察。结果:7例患者造血顺利恢复,ANC>0.5×109/L 平均为13 d,BPC>20×109/L 平均为11 d。+30天时经短串重复系列(STR蛳PCR)检测,7例植活患者中4例为完全嵌合状态(CDC),3例为混合嵌合体。+90天时又有1例患者转为CDC。中位随访6 (1~13) 个月,7例患者均无病生存。结论:非清髓性造血干细胞移植是慢粒慢性期、加速期的有效治疗手段,对于年龄较大患者亦有良好耐受性。
Objective: To observe the curative effect of non-myeloablative stem cell transplantation on chronic phase chronic phase (CML 蛳 CP) and slow phase accelerated phase (CML 蛳 AP). Methods: Fufang Hua (F) 30 mg / m2 × 6 d, busulfan (B) 4 mg · kg-1 · d-1 × 2 d, cyclophosphamide (CTX) 600 mg / d × 2 d , ± Ara 蛳 C preconditioning of seven cases of HLA matched patients, and hematopoietic recovery and other indicators of dynamic observation. Results: The hematopoietic function of 7 patients recovered smoothly, with an average of 13 days for ANC> 0.5 × 109 / L and 11 days for BPC> 20 × 109 / L. At +30 days, four of the seven patients undergoing colon cancer (CDC) were tested by short PCR (STR 蛳 PCR), and three were mixed chimeras. One more patient became CDC on +90 days. The median follow-up 6 (1 ~ 13) months, 7 patients were disease-free survival. Conclusion: Non-myeloablative hematopoietic stem cell transplantation is an effective treatment for chronic phase and chronic phase of chronic phase. It is also well tolerated in older patients.